跳转至内容
Merck
CN

E6910

Sigma-Aldrich

吡格列酮 盐酸盐

≥98% (HPLC), powder, hepatic gluconeogenesis blocker

别名:

5-[[4-[2-(5-一乙基-2-吡啶)乙氧基]苯基]甲基]-2,4-噻唑烷二酮 单盐酸盐

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C19H20N2O3S · HCl
分子量:
392.90
MDL编号:
UNSPSC代码:
41106305
PubChem化学物质编号:
NACRES:
NA.77

产品名称

吡格列酮 盐酸盐, ≥98% (HPLC)

质量水平

方案

≥98% (HPLC)

表单

powder

颜色

white to off-white

溶解性

DMSO: ≥10 mg/mL

创始人

Takeda

储存温度

room temp

SMILES字符串

Cl.CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1

InChI

1S/C19H20N2O3S.ClH/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17;/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23);1H

InChI key

GHUUBYQTCDQWRA-UHFFFAOYSA-N

基因信息

human ... PPARG(5468)

正在寻找类似产品? 访问 产品对比指南

一般描述

Pioglitazone hydrochloride consists of poly-morphs, form I and form II. It is an oral antidiabetic agent, that is a member of the thiazolidinedione group.

应用

Pioglitazone hydrochloride has been used:
  • to administer to mice model and treated the hepatoma cell line to study its effect on regulating insulin-degrading enzyme (IDE) in diet-induced obese (DIO) C57BL/6 mice
  • in drug preparation to analyze its effects on shortening and calcium transport in ventricular myocytes from the Goto-Kakizaki (GK) type 2 diabetic rat
  • to treat HepG2 cells with peroxisome proliferator-activated receptor γ (PPARγ) agonists to examine its effect on TOMM40-, APOE- and APOC1-mRNA levels

生化/生理作用

盐酸吡格列酮是一种PPARγ激动剂和噻唑烷二酮(TZD)抗糖尿病药物。吡格列酮是一种核受体过氧化物酶体增殖物激活受体γ(PPAR-γ)的选择性激动剂,并在较小程度上是PPAR-α
Pioglitazone hydrochloride is usually used to treat type-II diabetes. It has the ability to block hepatic gluconeogenesis.

特点和优势

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the AMPKs and Nuclear Receptors (PPARs) pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Takeda. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

象形图

Health hazardExclamation mark

警示用语:

Warning

危险声明

危险分类

Acute Tox. 4 Oral - Carc. 2

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Peter Ochodnicky et al.
European journal of pharmacology, 730, 51-60 (2014-03-04)
Peroxisome proliferator-activated receptor γ (PPARγ) agonists have been shown to ameliorate diabetic nephropathy, but much less are known about their effects in non-diabetic nephropathies. In the present study, metabolic parameters, blood pressure, aortic endothelial function along with molecular and structural
J R Colca et al.
Clinical pharmacology and therapeutics, 93(4), 352-359 (2013-03-07)
It may be possible to achieve insulin sensitivity through the recently identified mitochondrial target of thiazolidinediones (mTOT), thereby avoiding peroxisome proliferator-activated receptor-γ (PPAR-γ)-dependent side effects. In this phase IIb clinical trial, 258 patients with type 2 diabetes completed a 12-week
Romina Lomonaco et al.
Drugs, 73(1), 1-14 (2013-01-19)
Nonalcoholic fatty liver disease (NAFLD) is considered the most common liver disorder in the Western world. It is commonly associated with insulin resistance, obesity, dyslipidaemia, type 2 diabetes mellitus (T2DM) and cardiovascular disease. Nonalcoholic steatohepatitis (NASH) is characterized by steatosis
Andrew Grey et al.
European journal of endocrinology, 170(2), 255-262 (2013-11-13)
Preclinical studies, observational studies, and clinical trials suggest that thiazolidinediones (TZDs) reduce bone mineral density (BMD) and increase fracture risk. Most of the evidence on the skeletal effects of TZDs is from studies of rosiglitazone. We set out to investigate
Julien Lamontagne et al.
Diabetes, 62(6), 2122-2129 (2013-02-05)
Our objective was to determine if the insulin-sensitizing drug pioglitazone acutely reduces insulin secretion and causes metabolic deceleration in vivo independently of change in insulin sensitivity. We assessed glucose homeostasis by hyperinsulinemic-euglycemic and hyperglycemic clamp studies and energy expenditure by

商品

Discover Bioactive Small Molecules for ADME/Tox

Discover Bioactive Small Molecules for Lipid Signaling Research

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门